Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA

Related Clinical Trial
PR3-AAV Resilient Remission or PRRR Study on Pharmacokinetics of Meperizumab Injection and NUCALA® in Healthy Male Volunteers Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study of Mepolizumab-based Regimen Compared to Conventional Therapeutic Strategy in Patients With Eosinophilic Granulomatosis With Polyangiitis (E-merge) Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis Hydroxychloroquine in ANCA Vasculitis Evaluation Vasculitis Illness Perception (VIP) Study Reproductive Health in Men and Women With Vasculitis Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Impact of Vasculitis on Employment and Income Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases VCRC Tissue Repository Yellow Fever Vaccine in Patients With Rheumatic Diseases Journey of Patients With Vasculitis From First Symptom to Diagnosis One-Time DNA Study for Vasculitis Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Clinical Transcriptomics in Systemic Vasculitis (CUTIS) The ANCA Vasculitis Questionnaire (AAV-PRO©) Vasculitis Pregnancy Registry VCRC Patient Contact Registry Patient-Reported Data Validation Study Educational Needs of Patients With Systemic Vasculitis Diagnostic Effectiveness of Virtual Bronchoscopy Alemtuzumab for ANCA Associated Refractory Vasculitis Interventional Cryotherapy for the Eradication of Benign Airway Disease (“ICE the BAD”) PRagmatic Analysis of Vitamin D in ANCA-Associated Vasculitis Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides Plasma Exchange for Renal Vasculitis PRO Development for ANCA Associated Vasculitis BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides Rituximab Vasculitis Maintenance Study Anti-Cytokine Therapy for Vasculitis Rituximab and Belimumab Combination Therapy in PR3 COMBIVAS American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis Low-dose Glucocorticoid Vasculitis Induction Study Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis. The Assessment of Prednisone In Remission Trial (TAPIR) – Patient Centric Approach Steroids and Methotrexate to Treat Systemic Vasculitis Efficacy Study of Two Treatments in the Remission of Vasculitis Assessment of Lung Inflammation in Patients With Atopic Asthma Using Positron Emission Tomography The Assessment of Prednisone In Remission Trial – Centers of Excellence Approach Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener’s) Rituximab for the Treatment of Wegener’s Granulomatosis and Microscopic Polyangiitis Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener’s) and Microscopic Polyangiitis Mycophenolate Mofetil for Treatment of Relapses of Wegener’s Disease or Microscopic Polyangiitis (MPA) Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) Daclizumab to Treat Wegener’s Granulomatosis An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener’s Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies Etanercept to Treat Wegener’s Granulomatosis Treatment of Wegener’s Granulomatosis With Cyclophosphamide Mycophenolate Mofetil to Treat Wegener’s Granulomatosis and Related Vascular Inflammatory Conditions Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener’s Granulomatosis Comparison of Treatments to Maintain Disease Remission in Patients With Wegener’s Granulomatosis and Related Vasculitis Syndromes Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener’s Granulomatosis) Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study Analysis of Bronchial Tissue and Fluid in Patients With Wegener’s Granulomatosis TEMPO Study: Trimethoprim-Sulfamethoxazole in Granulomatosis With Polyangiitis Cardiovascular Involvement in Patients With Granulomatosis With Polyangiitis An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener’s) or Microscopic Polyangiitis Study of One Protein Implicated in Wegener Disease Abatacept in Treating Adults With Mild Relapsing Wegener’s Granulomatosis Phase II Study on Gusperimus in Patients With Refractory Wegener’s Granulomatosis Etanercept for Wegener’s Granulomatosis Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener’s Granulomatosis

Brief Title

Comparison of Tofacitinib and Methotrexate in the Maintained Treatment of GPA

Official Title

Randomized Trial of Tofacitinib Versus Methotrexate for Maintenance Therapy in Granulomatosis With Polyangiitis

Brief Summary

      The aim of this study is to identify the optimal maintenance therapy for granulomatosis with
      polyangiitis (GPA) by comparing the MTX (standard regimen) with Tofacitinib in terms of
      efficacy, i.e. in preventing relapses.
    

Detailed Description

      Granulomatosis with polyangiitis (GPA), a systemic small-vessel vasculitis, could involve
      multiple tissues and organs. Remission of GPA can be obtained in approximately 80% of the
      patients with a combination of corticosteroids and cyclophosphamide. However, relapses are
      frequent and remain a challenge. The optimal drug for maintenance treatment is not
      determined. Tofacitinib is a Jak inhibitor which has been proved to be effective in multiple
      inflammatory diseases such as rheumatoid arthritis. But the efficiency and safety of
      tofacitinib in treating GPA remains unclear yet. In the present randomized trial, the
      comparison of MTX (standard regimen) with Tofacitinib in terms of efficacy, i.e. in
      preventing relapses will be conducted.
    

Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Relapse rate (major or minor) at 12 months

Secondary Outcome

 Time to first relapse.

Condition

Granulomatosis With Polyangiitis

Intervention

Tofacitinib

Study Arms / Comparison Groups

 Tofactitinib
Description:  partcipants would be given one tablet of tofacitinib (5mg per tablet), twice per day, the treatment duration will last 12 months during the whole follow-up period.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

66

Start Date

July 1, 2021

Completion Date

July 1, 2024

Primary Completion Date

July 1, 2024

Eligibility Criteria

        Inclusion Criteria:

          1. Patients with newly diagnosed or relapsing Granulomatosis with polyangiitis met the
             criteria of 1990 ACR and 2012 Chapel Hill criteria

          2. Patients in disease flare have achieved remission using a treatment combining
             corticosteroids and IV cyclophosphamide

          3. Remission is defined as a Birmingham Vasculitis Activity/ Wegener's granulomatosis
             (BVAS/WG) score of 0 and receiving 10 mg/day of oral prednisone (or equivalent) at
             least 2 weeks

          4. Age 18 to 75 years

          5. Written informed consent obtained before taking part in the study

        Exclusion Criteria:

          1. Severe GPA defined as potentially organ- or life-threatening disease (i.e. alveolar
             haemorrhage, heart failure caused by myocarditis or pericarditis, progressive
             neurological symptoms, deaf, blindness, et al.)

          2. Serum creatinine>120umol/L or proteinuria>1.0g/d

          3. Failure to response after treatment with methotrexate or cyclophosphamide previously

          4. Receipt of a JAKi therapy previously

          5. Co-existence of another systemic autoimmune disease

          6. Secondary vasculitis (following neoplastic disease, an infection or antithyroid drugs)

          7. Malignancy or history of malignancy

          8. Infection by HIV, HCV, HBV or tuberculosis

          9. Severe uncontrolled cardiovascular, pulmonary, liver, gastrointestinal, endocrine,
             hematological, neurological, or psychiatric diseases that are not related to systemic
             vasculitis

         10. Allergic to any of the medication (cyclophosphamide, corticosteroids, tofacitinib,
             methotrexate)

         11. Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White
             blood cell count <3.0 x 109/L; Absolute neutrophil count <1.5 x 109/L; Platelet count
             <100 x 109/L; Alanine transaminase or aspartate aminotransferase or total
             bilirubin>1.5 upper normal limit; Estimated glomerular filtration rate<60ml/min/1.73m2

         12. Any medical or psychiatric disorder which, in the investigator's opinion, may prevent
             the administration of treatment and patient follow-up according to the protocol,
             and/or which may expose the patient to a too greater risk of an adverse effect.

         13. Incapacity or refusal to understand or sign the informed consent form.

         14. Pregnancy, breastfeeding.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Lindi Jiang, PhD, +8602164041990, [email protected]

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT04944524

Organization ID

TofMTX-GPA maintain


Responsible Party

Sponsor

Study Sponsor

Shanghai Zhongshan Hospital


Study Sponsor

Lindi Jiang, PhD, Study Chair, Fudan University


Verification Date

June 2021